Essential Partners’s Regeneron Pharmaceuticals REGN Stock Holding History

Essential Partners’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$619K	Buy	816 +103	+14%	+$77.8K	0.28%	57
2026 Q2	$445K	Sell	713 -22	-3%	-$15K	0.2%	89
2026 Q1	$568K	Sell	735 -872	-54%	-$668K	0.19%	132
2025 Q4	$1.24M	Buy	1,607 +434	+37%	+$295K	0.38%	63
2025 Q3	$660K	Buy	1,173 +1,165	+14,563%	+$659K	0.22%	126
2025 Q2	$4.2K	Buy	+8	New	+$4.46K	﹤0.01%	1101

Other funds holding REGN

GuoLine Advisory Singapore $1.16B AUM 31.35% 1-Year Est. Return

Atwood & Palmer Kansas City, Missouri $1.95B AUM 16% 1-Year Est. Return

Wedge Capital Management Charlotte, North Carolina $5.72B AUM 38.26% 1-Year Est. Return

MN Services Vermogensbeheer The Hague, Netherlands $13.4B AUM 37.34% 1-Year Est. Return

Czech National Bank Prague, Czech Republic $18.9B AUM 36.24% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return

IFM Investors Melbourne, Australia $16B AUM 33.69% 1-Year Est. Return

Woodstock Corp Boston, Massachusetts $1.24B AUM 22.02% 1-Year Est. Return

SBWIC

Schaper Benz & Wise Investment Counsel Neenah, Wisconsin $1.51B AUM 27.44% 1-Year Est. Return

NPPM

North Point Portfolio Managers Orange Village, Ohio $595M AUM 14.89% 1-Year Est. Return

Essential Partners's REGN Position: Q3 2026 in Review

Essential Partners increased its Regeneron Pharmaceuticals (REGN) stake by 14% in Q3 2026, buying an estimated $77.8K and bringing the position to 816 shares worth $619K. The position accounts for 0.28% of the portfolio, ranked #57.

Essential Partners first reported a position in REGN in Q2 2025 and has held it in 6 quarters since. The position peaked at $1.24M in Q4 2025. 122 funds tracked by Wall St. Rank hold REGN as of Q3 2026.

Essential Partners held 816 shares of Regeneron Pharmaceuticals worth $619K as of Q3 2026.
Essential Partners bought 103 Regeneron Pharmaceuticals shares in Q3 2026, an estimated $77.8K.
Regeneron Pharmaceuticals made up 0.28% of Essential Partners's portfolio in Q3 2026, its #57 holding.
Essential Partners first reported a position in Regeneron Pharmaceuticals in Q2 2025 and has held it in 6 quarters since.
Essential Partners's Regeneron Pharmaceuticals position peaked at $1.24M in Q4 2025.
122 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2026.

Based on Essential Partners's 13F filing for Q3 2026, filed 14 Oct 2026.